Cases & Deals

  • Home
  • Practices
  • Athersys establishes equity purchase facility for sale of up to $100 million of Common Stock to Aspire Capital Fund LLC

Share

Athersys establishes equity purchase facility for sale of up to $100 million of Common Stock to Aspire Capital Fund LLC

July 2021

Client(s) Athersys, Inc.

Jones Day represented Athersys, Inc. in connection with the establishment of an equity purchase facility for the sale of up to $100 million of Athersys’ shares of Common Stock to Aspire Capital Fund LLC. Athersys (NASDAQ: ATHX) is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Athersys is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.